We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+4.2%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$208M
AUM Growth
-$25.1M
Cap. Flow
-$39.5M
Cap. Flow %
-18.99%
Top 10 Hldgs %
75.53%
Holding
46
New
9
Increased
5
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
CNXR
Connecture, Inc.
CNXR
+$49.4M
2
ARWR icon
Arrowhead Research
ARWR
+$7.67M
3
TOVX icon
Theriva Biologics
TOVX
+$6.14M
4
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$4.6M
5
AGEN
Agenus
AGEN
+$2.89M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$22M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$11.7M
3
AMBI
Ambit Biosciences Corp
AMBI
+$9.24M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$7.5M
5
FLNA
Filana Therapeutics
FLNA
+$7.11M

Sector Composition

Rank Sector Weight
1 Healthcare 51.88%
2 Technology 23.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$503K 0.24%
+45,938
New +$455K
ANTH
27
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$395K 0.19%
31,250
-147,650
-83% -$2.14M
PLX icon
28
Protalix BioTherapeutics
PLX
$191M
$392K 0.19%
+21,322
New +$458K
ACHV icon
29
Achieve Life Sciences
ACHV
$659M
– –
-815
Closed -$4.79M
AMRN
30
Amarin Corp
AMRN
$299M
– –
-46,177
Closed -$1.01M
ARCT icon
31
CALL
Arcturus Therapeutics
ARCT
$164M
– –
-69,600
Closed -$7.52M
ARCT icon
32
PUT
Arcturus Therapeutics
ARCT
$164M
– –
-5,171
Closed -$559K
LRMR icon
33
Larimar Therapeutics
LRMR
$397M
– –
-1,405
Closed -$331K
NBIX icon
34
Neurocrine Biosciences
NBIX
$16.8B
– –
-1,161,739
Closed -$22M
FLNA
35
Filana Therapeutics
FLNA
$48.8M
– –
-259,698
Closed -$7.11M
TVRD
36
Tvardi Therapeutics
TVRD
$19.7M
– –
-1,314
Closed -$397K
CUTR
37
DELISTED
Cutera, Inc.
CUTR
– –
-315,000
Closed -$3.18M
VIRX
38
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-1,905
Closed -$2.86M
ISEE
39
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-300,000
Closed -$11.7M
CCXI
40
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-483,741
Closed -$2.18M
CASC
41
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-651,325
Closed -$7.5M
WGBS
42
DELISTED
WaferGen Bio-systems, Inc.
WGBS
– –
-84,302
Closed -$1.83M
HTWR
43
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-70,000
Closed -$5.43M
THOR
44
DELISTED
THORATEC CORPORATION
THOR
– –
-22,300
Closed -$596K
AMBI
45
DELISTED
Ambit Biosciences Corp
AMBI
– –
-600,000
Closed -$9.24M
SPHS
46
DELISTED
Sophiris Bio, Inc.
SPHS
– –
-1,585,500
Closed -$4.65M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2014 Portfolio in Review

As of Q4 2014, Great Point Partners held 46 positions worth $208M, down 11% from $233M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Great Point Partners withdrew a net $39.5M in Q4 2014, closing 18 positions and reducing 9 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $22M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 71% a quarter earlier, followed by Technology.

Against the trend, Great Point Partners opened a new position in Connecture, Inc. worth $49.6M.

  • Great Point Partners's largest Q4 2014 buy was Connecture, Inc.: 5,502,965 shares worth $49.6M.
  • Great Point Partners added most to HYPERION THERAPEUTICS INC COM STK (DE) in Q4 2014, an estimated $4.6M increase.
  • Great Point Partners's biggest Q4 2014 reduction was Infinity Pharmaceuticals, Inc., cutting an estimated $6.92M.
  • Great Point Partners fully exited Neurocrine Biosciences in Q4 2014, selling an estimated $22M.
  • Great Point Partners's ten largest holdings make up 76% of its $208M portfolio in Q4 2014.
  • Great Point Partners opened 9 new positions and closed 18 in Q4 2014.
  • Great Point Partners's portfolio value fell 11% quarter-over-quarter to $208M.

Based on Great Point Partners's 13F filing for Q4 2014, filed 17 Feb 2015.